Influenza Vaccine Market Forecasts to 2028 - Global Analysis By Vaccine Type (Trivalent and Quadrivalent), Type (Pandemic, Seasonal and Other Types), Technology (Egg-Based and Cell-Based), Age Group, Route of Administration, Distribution Channel and By Geography
|
Years Covered |
2020-2028 |
|
Estimated Year Value (2022) |
US $8.11 BN |
|
Projected Year Value (2028) |
US $19.34 BN |
|
CAGR (2022 - 2028) |
15.58% |
|
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
|
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
|
Largest Market |
North America |
|
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Influenza Vaccine Market is accounted for $8.11 billion in 2022 and is expected to reach $19.34 billion by 2028 growing at a CAGR of 15.58% during the forecast period. The influenza virus is what causes the contagious respiratory ailment known as influenza. Fever, coughing, soreness in the muscles and joints, headaches, and extreme exhaustion are all symptoms of influenza. Flu-related illness can range from mild to severe, and it can occasionally be fatal. For the purpose of preventing influenza infections, vaccinations are advised. The urgent need for an effective influenza vaccine is being driven by the swift global spread of influenza virus epidemics. The main driver fueling the market's expansion throughout the projection period is a strong product pipeline.
According to the Centers for Disease Control and Prevention in 2020, flu resulted in 9 million and 41 million illnesses with 140,000 to 710,000 hospitalizations. According to the World Health Organization (WHO), 2018, influenza cases related hospitalization ranges in 3-5 million cases for severe illness, whereas deaths related to influenza are about 290,000 to 650,000.
Market Dynamics:
Driver:
Rise with increasing government support for immunization
Government support and surveillance of influenza vaccination are increasing, which is driving the market expansion for influenza vaccines globally. The administration, distribution, and supply of influenza vaccines must be monitored on both a global and national scale through surveillance. However, a number of nations have various labelling standards along with lengthy deadlines. This makes the procedure of carrying out clinical trials on a worldwide scale even more complicated.
Restraint:
Difficulty in diagnosis
Because influenza's most obvious symptoms, such as aches, coughs, and fevers, are similar to many other common illnesses, diagnosing influenza can be challenging. There are numerous methods for figuring out whether a patient is infected with the flu or not. However, most patients do not seek an influenza diagnosis. The likelihood of false positive or false negative test results has an impact on the adoption rate. Although there are sophisticated diagnostic methods for the precise detection of influenza infection, the time it takes to receive the results of those tests can be several days. This delays diagnosis and eventually lowers the demand for the medication. All of these elements could limit the market's expansion for flu vaccines during the anticipated period.
Opportunity:
The need for revaccination
The patient may need to be hospitalised with the potentially lethal illness of influenza. The best method of preventing influenza is vaccination because prevention is always preferable to treatment. To ensure optimal protection, vaccinations should be administered yearly prior to the start of flu season. Due to the antigenic drift of influenza viruses with time and the waning of vaccine-specific antibodies, this repeated dose is necessary. Additionally, the CDC advises getting the seasonal flu shot every year as the most effective strategy to lower your chance of contracting the illness. Therefore, revaccination aids in boosting vaccine sales which drives influenza vaccine market growth.
Threat:
Manufacturing delays
The market for influenza vaccinations is a difficult one for a number of reasons. Seasonal influenza vaccines need to be developed and delivered in a short period of time—six months—in addition to requiring yearly upgrades. Losses of revenue and market share may be the result of manufacturing delays and decreased output. In addition, the demand for seasonal influenza vaccines varies and is frequently unpredictable due to variables including the weather, the timing and length of the influenza season, the availability of the vaccine, and vaccination knowledge among the general public. Planning for manufacturing is challenging due to these issues. Even more unpredictably, the pandemic influenza vaccine industry relies nearly entirely on government stockpiles and supply agreements.
Covid-19 Impact
The coronavirus pandemic has an impact on the global routine immunisation programmes and campaigns run in developed and poor nations. However, during the pandemic, vaccination rates rose as a result of a number of factors, including pressure from health departments and the expansion of government programmes offering free flu shots. Another factor influencing the uptake of flu vaccines is the public's rising knowledge of the increased risk of contracting COVID19 if the flu weakens the immune system.
The inactivated segment is expected to be the largest during the forecast period
The inactivated segment is estimated to have a lucrative growth, due to the fact that inactivated vaccines are standardised based on the particular virus strain, there is an increase in demand for them in both developing and developed nations. This feature of the vaccines aids in reducing the flu in a shorter amount of time and reversing any beneficial effects. The rising demand and increased influenza prevalence are to
The hospital & retail pharmacies segment is expected to have the highest CAGR during the forecast period
The hospital & retail pharmacies segment is anticipated to witness the fastest CAGR growth during the forecast period, due to vaccination being commonly favoured and being done at smaller institutions, this leading position has developed. In the coming years, a high market value is anticipated in part due to the hospitals' enormous supply of vaccines.
Region with highest share:
North America is projected to hold the largest market share during the forecast period owing to the presence of major players in the area is responsible for the region's dominance in the market. Additionally, improvements in vaccine delivery, a greater focus on immunisation programmes by the government, the creation of innovative vaccines, and an increase in seasonal influenza prevalence are all key revenue-generators in the influenza vaccine industry.
Region with highest CAGR:
Asia Pacific is projected to have the highest CAGR over the forecast period, owing to rapid economic development, rising disposable income, government initiatives, and rising seasonal influenza incidence are some key factors that are likely to fuel revenue generation opportunities in the market. Government concentration is also increasing in Asian countries to improve healthcare facilities.
Key players in the market
Some of the key players profiled in the Influenza Vaccine Market include Csl Limited (Seqirus GmbH), Emergent Biosolutions, Astrazeneca Plc (Astrazeneca), Glaxosmithkline Plc, F. Hoffmann-La Roche Ltd., Biodiem, Merck & Co., Inc. (Merck Sharp & Dohme Corp.), Sanofi, Sinovac Biotech Ltd., Novartis Ag, Pfizer, Inc., Gamma Vaccines Pty Ltd., Seqirus, Moderna TX, Abbott.
Key Developments:
In March 2022, Seqirus announced the approval of Flucelvax quadrivalent, a cell based influenza vaccine for individuals in the age group of two years and older. This approval by Health Canada made children in the age group of 2 to 18 years eligible for these vaccines.
In September 2021, Sanofi acquired Translate Bio, a clinical-stage mRNA therapeutics company, for the development of new and seasonal vaccines for influenza.
In February 2021, GlaxoSmithKline plc expanded a pre-existing collaboration with Vir Biotechnology with an aim to develop monoclonal antibodies for the prevention and treatment of influenza.
In January 2021, ModernaTX, Inc. announced that the company has planned to utilize mRNA technology to develop and manufacture influenza, HIV, and Nipah virus vaccines.
In February 2020, BioDiem announced the approval of Changchun BCHT Biotechnology Co (BCHT)’s LAIV vaccine by the Chinese National Medical Products Administration (NMPA).
In February 2020, Abbott launched a new inactivated quadrivalent vaccine for use in children below three years of age. This new launch expanded the company’s established pharmaceutical portfolio and the spread of flu vaccines to a critical market such as India.
Vaccine Types Covered:
• Trivalent
• Quadrivalent
Types Covered:
• Pandemic
• Seasonal
• Inactivated
• Live Attenuated
• Other Types
Technologies Covered:
• Egg-Based
• Cell-Based
Age Groups Covered:
• Pediatric
• Adult
Route of Administrations Covered:
• Injection
• Nasal Spray
Distribution Channels Covered:
• Hospital & Retail Pharmacies
• Government Suppliers
• Other Distribution Channels
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Technology Analysis
3.7 Emerging Markets
3.8 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Influenza Vaccine Market, By Vaccine Type
5.1 Introduction
5.2 Trivalent
5.3 Quadrivalent
6 Global Influenza Vaccine Market, By Type
6.1 Introduction
6.2 Pandemic
6.3 Seasonal
6.4 Inactivated
6.5 Live Attenuated
6.6 Other Types
7 Global Influenza Vaccine Market, By Technology
7.1 Introduction
7.2 Egg-Based
7.3 Cell-Based
8 Global Influenza Vaccine Market, By Age Group
8.1 Introduction
8.2 Pediatric
8.3 Adult
9 Global Influenza Vaccine Market, By Route of Administration
9.1 Introduction
9.2 Injection
9.3 Nasal Spray
10 Global Influenza Vaccine Market, By Distribution Channel
10.1 Introduction
10.2 Hospital & Retail Pharmacies
10.3 Government Suppliers
10.4 Other Distribution Channels
11 Global Influenza Vaccine Market, By Geography
11.1 Introduction
11.2 North America
11.2.1 US
11.2.2 Canada
11.2.3 Mexico
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 Italy
11.3.4 France
11.3.5 Spain
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 New Zealand
11.4.6 South Korea
11.4.7 Rest of Asia Pacific
11.5 South America
11.5.1 Argentina
11.5.2 Brazil
11.5.3 Chile
11.5.4 Rest of South America
11.6 Middle East & Africa
11.6.1 Saudi Arabia
11.6.2 UAE
11.6.3 Qatar
11.6.4 South Africa
11.6.5 Rest of Middle East & Africa
12 Key Developments
12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies
13 Company Profiling
13.1 Csl Limited (Seqirus GmbH)
13.2 Emergent Biosolutions
13.3 Astrazeneca Plc (Astrazeneca)
13.4 Glaxosmithkline Plc
13.5 F. Hoffmann-La Roche Ltd.
13.6 Biodiem
13.7 Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
13.8 Sanofi
13.9 Sinovac Biotech Ltd.
13.10 Novartis Ag
13.11 Pfizer, Inc.
13.12 Gamma Vaccines Pty Ltd.
13.13 Seqirus
13.14 Moderna TX
13.15 Abbott
List of Tables
1 Global Influenza Vaccine Market Outlook, By Region (2020-2028) ($MN)
2 Global Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
3 Global Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
4 Global Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
5 Global Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
6 Global Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
7 Global Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
8 Global Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
9 Global Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
10 Global Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
11 Global Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
12 Global Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
13 Global Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
14 Global Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
15 Global Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
16 Global Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
17 Global Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
18 Global Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
19 Global Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
20 Global Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
21 Global Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
22 Global Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
23 Global Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
24 North America Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
25 North America Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
26 North America Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
27 North America Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
28 North America Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
29 North America Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
30 North America Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
31 North America Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
32 North America Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
33 North America Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
34 North America Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
35 North America Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
36 North America Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
37 North America Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
38 North America Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
39 North America Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
40 North America Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
41 North America Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
42 North America Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
43 North America Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
44 North America Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
45 North America Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
46 North America Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
47 Europe Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
48 Europe Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
49 Europe Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
50 Europe Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
51 Europe Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
52 Europe Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
53 Europe Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
54 Europe Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
55 Europe Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
56 Europe Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
57 Europe Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
58 Europe Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
59 Europe Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
60 Europe Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
61 Europe Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
62 Europe Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
63 Europe Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
64 Europe Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
65 Europe Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
66 Europe Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
67 Europe Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
68 Europe Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
69 Europe Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
70 Asia Pacific Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
71 Asia Pacific Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
72 Asia Pacific Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
73 Asia Pacific Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
74 Asia Pacific Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
75 Asia Pacific Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
76 Asia Pacific Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
77 Asia Pacific Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
78 Asia Pacific Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
79 Asia Pacific Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
80 Asia Pacific Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
81 Asia Pacific Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
82 Asia Pacific Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
83 Asia Pacific Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
84 Asia Pacific Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
85 Asia Pacific Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
86 Asia Pacific Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
87 Asia Pacific Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
88 Asia Pacific Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
89 Asia Pacific Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
90 Asia Pacific Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
91 Asia Pacific Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
92 Asia Pacific Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
93 South America Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
94 South America Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
95 South America Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
96 South America Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
97 South America Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
98 South America Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
99 South America Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
100 South America Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
101 South America Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
102 South America Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
103 South America Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
104 South America Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
105 South America Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
106 South America Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
107 South America Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
108 South America Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
109 South America Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
110 South America Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
111 South America Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
112 South America Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
113 South America Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
114 South America Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
115 South America Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
116 Middle East & Africa Influenza Vaccine Market Outlook, By Country (2020-2028) ($MN)
117 Middle East & Africa Influenza Vaccine Market Outlook, By Vaccine Type (2020-2028) ($MN)
118 Middle East & Africa Influenza Vaccine Market Outlook, By Trivalent (2020-2028) ($MN)
119 Middle East & Africa Influenza Vaccine Market Outlook, By Quadrivalent (2020-2028) ($MN)
120 Middle East & Africa Influenza Vaccine Market Outlook, By Type (2020-2028) ($MN)
121 Middle East & Africa Influenza Vaccine Market Outlook, By Pandemic (2020-2028) ($MN)
122 Middle East & Africa Influenza Vaccine Market Outlook, By Seasonal (2020-2028) ($MN)
123 Middle East & Africa Influenza Vaccine Market Outlook, By Inactivated (2020-2028) ($MN)
124 Middle East & Africa Influenza Vaccine Market Outlook, By Live Attenuated (2020-2028) ($MN)
125 Middle East & Africa Influenza Vaccine Market Outlook, By Other Types (2020-2028) ($MN)
126 Middle East & Africa Influenza Vaccine Market Outlook, By Technology (2020-2028) ($MN)
127 Middle East & Africa Influenza Vaccine Market Outlook, By Egg-Based (2020-2028) ($MN)
128 Middle East & Africa Influenza Vaccine Market Outlook, By Cell-Based (2020-2028) ($MN)
129 Middle East & Africa Influenza Vaccine Market Outlook, By Age Group (2020-2028) ($MN)
130 Middle East & Africa Influenza Vaccine Market Outlook, By Pediatric (2020-2028) ($MN)
131 Middle East & Africa Influenza Vaccine Market Outlook, By Adult (2020-2028) ($MN)
132 Middle East & Africa Influenza Vaccine Market Outlook, By Route of Administration (2020-2028) ($MN)
133 Middle East & Africa Influenza Vaccine Market Outlook, By Injection (2020-2028) ($MN)
134 Middle East & Africa Influenza Vaccine Market Outlook, By Nasal Spray (2020-2028) ($MN)
135 Middle East & Africa Influenza Vaccine Market Outlook, By Distribution Channel (2020-2028) ($MN)
136 Middle East & Africa Influenza Vaccine Market Outlook, By Hospital & Retail Pharmacies (2020-2028) ($MN)
137 Middle East & Africa Influenza Vaccine Market Outlook, By Government Suppliers (2020-2028) ($MN)
138 Middle East & Africa Influenza Vaccine Market Outlook, By Other Distribution Channels (2020-2028) ($MN)
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.